Summary We aimed to determine the effects of bisphosphonates on mechanical properties independent of changes in bone density. Our results show that at equivalent bone densities, vertebrae from beagles treated with bisphosphonate have equivalent bone strength and reduced bone energy absorption compared to those from untreated animals. Introduction Assessing the relationship between mechanical properties and bone density allows a biomechanical evaluation of bone quality, with differences at a given density indicative of altered quality. The purpose of this study was to evaluate the strength-density and energy absorption-density relationships in vertebral bone following a one-year treatment with clinical doses of two different bisphosphonates in beagle dogs. Methods Areal bone mineral density (aBMD) and compressive mechanical properties (ultimate load and energy absorption) were assessed on lumbar vertebrae from skeletally mature beagle dogs treated with vehicle (VEH), alendronate (ALN), or risedronate (RIS). Relationships among properties were assessed using analyses of covariance.
Introduction
Bone mineral density (BMD) provides a convenient means of assessing fracture risk, but it is well-accepted that skeletal factors other than BMD contribute to fracture prevention [1, 2] . This is illustrated clinically by the disproportionate changes in BMD and fracture risk reduction with antiremodeling treatments, with variable changes in BMD associated with similar reductions in fracture [3] [4] [5] . Such data have led to numerous studies evaluating the effect of remodeling suppression on factors other than bone density that contribute to a bone's fracture resistance [6] .
A bone's fracture resistance is determined by a combination of factors [7] . For simplicity, these factors are often times considered to include bone mass and 'everything else'. Bone mass can be variably defined, yet clinically is routinely measured as areal BMD (aBMD), a composite variable influenced by both bone mass (volume), bone size and mineralization. The 'everything else', often encompassed by the term bone quality, includes factors such as whole bone geometry, microarchitecture, porosity, mineralization, collagen organization and cross-linking, and microdamage accumulation. Recently, Hernandez and Keaveny [6] proposed that bone quality can be defined by examining the relationship between measures of bone biomechanical performance and bone density, with a change in the relationship indicative of a change in bone quality. Any change in bone strength or energy to fracture not accounted for by a change in bone mass (aBMD) must be accounted for by other measures of bone as defined above [6] . If a treatment has no effect on bone quality then the strengthdensity relationships would be similar to untreated bone. Conversely, if a treatment alters bone quality (either positively or negatively) then the strength-density curve would differ relative to untreated bone. Although this approach does not address which component of bone quality is altered, it does provide a useful starting point to determine if treatments alter biomechanical properties through density-dependent or density-independent mechanisms. We have previously documented that the bisphosphonates risedronate and alendronate increase the strength (∼10%) and stiffness (∼20%) of dog vertebrae following one-year treatment, but reduce toughness nonsignificantly at doses used for the clinical treatment of osteoporosis [8, 9] , and significantly at doses used for the treatment of Paget's disease [10] . The goal of this study was to determine if these anti-remodeling agents alter vertebral bone quality through assessment of the strength-density and energy absorption-density relationships.
Methods
Detailed methods regarding experimental design and tissue analyses have been previously reported [8, 9] . Briefly, skeletally mature (range: 1-2 years old at initiation of study; mean age 1.3 years) female beagle dogs (n=36; 12/ group) were treated daily for 1 year with oral doses of saline vehicle (VEH), risedronate (RIS), or alendronate (ALN). The doses of RIS (0.10 mg/kg/day) and ALN (0.20 mg/kg/day) represent the doses used to treat postmenopausal osteoporosis on a mg/kg basis. Following one year of treatment, the fourth lumbar vertebra was excised and assessed for areal bone mineral density (aBMD, PIXImus densitometer). We chose to assess relationships using aBMD as this technique is used clinically to evaluate vertebrae bone density. Following endplate removal, bones were tested in compression (10 mm/min) to determine mechanical properties. Ultimate load was defined as the maximal load achieved during the test, while energy absorption was defined as the area under the load/displacement curve up to the point of ultimate load. The strengthdensity and energy absorption-density relationships were compared among groups using analyses of covariance. When groups had similar slopes, least square means (LSM) were compared to determine differences in parameters after accounting for aBMD. For all tests, p<0.05 was considered significant.
Results
As previously described, vertebral aBMD was significantly increased with ALN (0.36+0.02 g/cm 2 ), but not RIS (0.33+ 0.02 g/cm 2 ), compared to VEH (0.33+0.02 g/cm 2 ) [8] . There was no significant difference in the strength-density relationship between VEH (y=17264×−1927.2) and either RIS or ALN nor between the two bisphosphonates together (pooled y=16709×−1724.8) (Fig. 1a) .
There was no significant difference among groups in the slope of the energy absorption-density relationship, yet the intercepts differed significantly (Fig. 1b) . After adjusting for aBMD, the energy absorption capacity was significantly lower in ALN-treated specimens compared to both VEH (LSM=−22%, p=0.02) and RIS (LSM=−14%, p=0.02). There was no significant difference between VEH and RIS (p=0.12) for energy absorption after accounting for differences in aBMD.
Discussion
Anti-remodeling agents are clearly beneficial for reducing fracture risk in post-menopausal osteoporotic women, as well as various other populations. Despite this clear efficacy, the mechanism of fracture risk reduction with these agents is poorly understood beyond the suppression of osteoclast activity. The current study shows that any change in vertebral bone strength with bisphosphonate treatment can be explained entirely by increased density. Additionally, these data show that alendronate-treated bone, but not risedronate-treated bone, required significantly less energy to fracture than untreated controls at a given bone density.
The current study shows bisphosphonates enhance compressive vertebral bone strength by increasing bone density: the regression line depicting the strength-density relationship is not significantly different for either RIS or ALN treatments compared to VEH. As we have previously noted, the increases in vertebral compressive strength with ALN and RIS were 10% and 9.5%, respectively, both nonsignificant [8] . We have also previously reported no difference in the ultimate load to aBMD ratio between vehicle-and bisphosphonate-treated specimens [9] . Assessing the relationship between biomechanical properties using the current method (regression analyses) as opposed to using the ratio of strength/density of each specimen provides different information, yet the two are not mutually exclusive [6] . If the relationships are linear, with non-zero intercepts (as they are here, see Fig. 1 ), or if the relationships are non-linear, the ratios can differ even when the data follow the same relationship. It is, therefore, important to use both approaches (ratios and strength-density plots) to comprehensively assess changes in bone quality.
In addition to bone strength, the energy absorption capacity of a bone is important to determine fracture resistance [11] . After accounting for increased density with alendronatetreatment, the energy absorption capacity is significantly impaired compared to specimens from animals treated with VEH (−22%) and RIS (−14%). This is contrasted to risedronate-treatment, which did not significantly alter the energy absorption-density relationship compared to vehicle. The reduced energy absorption capacity per unit aBMD in ALN-treated animals is consistent with previous results showing a trend toward reduced bone toughness, the tissue's ability to absorb energy, at doses used for the treatment of osteoporosis [9] and significant reductions in toughness at doses used for the treatment of Paget's disease [10] . This suggests an additional increment in vertebral BMD is necessary with alendronate treatment to maintain energy absorption capacity at a level comparable to non-treated bone.
These data emphasize the importance of examining changes in numerous biomechanical properties, as the relationships between strength and density, and between energy to failure and density, were different for a given treatment. In addition, it remains unclear whether bone strength, energy absorption, or some other biomechanical parameter is most directly related to clinical fracture risk of the spine. Bone strength and energy absorption are believed to be governed by different parameters. The mineral component plays a significant role in determining the preyield properties of bone strength and stiffness [12, 13] , whereas the organic component dominates the post-yield deformation that accounts for energy absorption [14] . Therefore, treatment-induced changes in mineral-or collagen-related bone quality parameters may only manifest in those biomechanical properties in which each is predominant. Numerous studies [15] [16] [17] have shown that bisphosphonates increase average tissue mineralization as well as mineralization homogeneity. This is consistent with our data that show increased strength associated with increased aBMD following bisphosphonate treatment. We have shown alterations to collagen maturity and crosslinking of vertebral bone in dogs following one-year treatment with bisphosphonates [18] . The non-enzymatic glycation of bone caused by bisphosphonate treatment has been shown to reduce post-yield deformation of bone [19] . Increased formation of non-enzymatically-mediated cross links (such as pentosidine) is consistent with the aBMDnormalized reduction in energy to fracture demonstrated here. Changes in microarchitecture could also play a role, as even with similar bone volumes, subtle changes in the trabecular architecture could alter various mechanical properties including energy absorption [20, 21] .
In clinical trials, alendronate has been shown to produce greater remodeling suppression than risedronate [22] . Analyses of turnover suppression in the canine vertebrae in this study showed similar suppression at potencyequivalent doses of ALN and RIS relative to VEH-treated animals (−66 and 74%, respectively) [8] . Differences in turnover rates, or rather the degree of turnover suppression, would produce differences in microarchitecture as well as properties of the material that are dictated by remodeling rate (e.g., mineralization, collagen cross-linking, and microdamage). Whether these non-significant differences in turnover suppression between ALN and RIS in this study account for the different results with respect to the aBMDenergy absorption relationship is unclear.
These data should be considered in the context of various limitations. The use of intact, non-ovariectomized beagle dogs may limit the translation of these results to post-menopausal women. In addition, we have also only assessed one site (vertebra) and, therefore cannot definitively state whether these changes in bone quality are applicable to other clinically-relevant bone sites. Finally, as the goal of this study was to determine to relative contribution of aBMD and 'everything else' to the whole bone mechanical properties, these data do not specifically address the mechanism by which alendronate reduces bone quality with respect to energy absorption. To address such issues, specific material-level mechanical tests such as those using samples with defined geometry or micromechanical tests including nanoindentation, are necessary.
In conclusion, these data document bisphosphonates exert a positive effect on vertebral bone strength through increases in density. The data also show that alendronate, but not risedronate, significantly reduces vertebral energy required to fracture, when normalized by bone density. Given the known role of the organic matrix in determining energy absorption capacity, some effort should be made to determine the effects of bisphosphonate treatment on the amount, maturity and cross-linking of the collagen moiety in bone matrix and its role in altering mechanical properties.
